| __timestamp | Novartis AG | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 14993000000 | 675200000 |
| Thursday, January 1, 2015 | 14247000000 | 771800000 |
| Friday, January 1, 2016 | 14192000000 | 1205500000 |
| Sunday, January 1, 2017 | 14997000000 | 1146500000 |
| Monday, January 1, 2018 | 16471000000 | 1125800000 |
| Tuesday, January 1, 2019 | 14369000000 | 1166100000 |
| Wednesday, January 1, 2020 | 14197000000 | 1175500000 |
| Friday, January 1, 2021 | 14886000000 | 1111400000 |
| Saturday, January 1, 2022 | 14253000000 | 1210100000 |
| Sunday, January 1, 2023 | 12489000000 | 1274600000 |
| Monday, January 1, 2024 | 12566000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: Novartis AG and Perrigo Company plc, from 2014 to 2023. Over this period, Novartis AG consistently reported higher SG&A expenses, averaging around 13 times more than Perrigo. Notably, Novartis's expenses peaked in 2018, reaching approximately 16.5 billion, while Perrigo's expenses showed a steady increase, culminating in 2023 with a 90% rise from 2014. This trend highlights Novartis's expansive operational scale and Perrigo's strategic growth. Understanding these financial dynamics offers valuable insights into each company's operational strategies and market positioning.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Perrigo Company plc
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Novartis AG and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Perrigo Company plc
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.